38 related articles for article (PubMed ID: 19179889)
1. Ceramide Analog 5cc Overcomes TRAIL Resistance by Enhancing JNK Activation and Repressing XIAP Expression in Metastatic Colon Cancer Cells.
Huang Q; Liu F
Chemotherapy; 2023; 68(4):210-218. PubMed ID: 37429260
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.
Carter BZ; Gronda M; Wang Z; Welsh K; Pinilla C; Andreeff M; Schober WD; Nefzi A; Pond GR; Mawji IA; Houghten RA; Ostresh J; Brandwein J; Minden MD; Schuh AC; Wells RA; Messner H; Chun K; Reed JC; Schimmer AD
Blood; 2005 May; 105(10):4043-50. PubMed ID: 15687241
[TBL] [Abstract][Full Text] [Related]
3. Increased migration and motility in XIAP-null cells mediated by the C-RAF protein kinase.
Russell LG; Davis LAK; Hunter JE; Perkins ND; Kenneth NS
Sci Rep; 2022 May; 12(1):7943. PubMed ID: 35562367
[TBL] [Abstract][Full Text] [Related]
4. Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing.
Laure A; Rigutto A; Kirschner MB; Opitz L; Grob L; Opitz I; Felley-Bosco E; Hiltbrunner S; Curioni-Fontecedro A
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345150
[TBL] [Abstract][Full Text] [Related]
5. Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications.
Zhang BJ; Chen D; Dekker FJ; Quax WJ
Cancer Drug Resist; 2020; 3(4):791-803. PubMed ID: 35582230
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases.
Shanmugam G; Rakshit S; Sarkar K
Transl Oncol; 2022 Feb; 16():101312. PubMed ID: 34922087
[TBL] [Abstract][Full Text] [Related]
7. The application of histone deacetylases inhibitors in glioblastoma.
Chen R; Zhang M; Zhou Y; Guo W; Yi M; Zhang Z; Ding Y; Wang Y
J Exp Clin Cancer Res; 2020 Jul; 39(1):138. PubMed ID: 32682428
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases.
Gatla HR; Muniraj N; Thevkar P; Yavvari S; Sukhavasi S; Makena MR
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30841513
[TBL] [Abstract][Full Text] [Related]
9. The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.
Cao F; Zwinderman MRH; Dekker FJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498635
[TBL] [Abstract][Full Text] [Related]
10. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
Bononi A; Napolitano A; Pass HI; Yang H; Carbone M
Expert Rev Respir Med; 2015 Oct; 9(5):633-54. PubMed ID: 26308799
[TBL] [Abstract][Full Text] [Related]
11. CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186.
Zheng J; Li XD; Wang P; Liu XB; Xue YX; Hu Y; Li Z; Li ZQ; Wang ZH; Liu YH
Oncotarget; 2015 Sep; 6(28):25339-55. PubMed ID: 26231038
[TBL] [Abstract][Full Text] [Related]
12. Onconase mediated NFKβ downregulation in malignant pleural mesothelioma.
Goparaju CM; Blasberg JD; Volinia S; Palatini J; Ivanov S; Donington JS; Croce C; Carbone M; Yang H; Pass HI
Oncogene; 2011 Jun; 30(24):2767-77. PubMed ID: 21317924
[TBL] [Abstract][Full Text] [Related]
13. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.
Kauh J; Fan S; Xia M; Yue P; Yang L; Khuri FR; Sun SY
PLoS One; 2010 Apr; 5(4):e10376. PubMed ID: 20442774
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
Paik PK; Krug LM
J Thorac Oncol; 2010 Feb; 5(2):275-9. PubMed ID: 20035240
[TBL] [Abstract][Full Text] [Related]
15. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.
Symanowski J; Vogelzang N; Zawel L; Atadja P; Pass H; Sharma S
J Thorac Oncol; 2009 Feb; 4(2):149-60. PubMed ID: 19179889
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P
Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775
[TBL] [Abstract][Full Text] [Related]
17. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
[TBL] [Abstract][Full Text] [Related]
18. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
Gillespie S; Borrow J; Zhang XD; Hersey P
Apoptosis; 2006 Dec; 11(12):2251-65. PubMed ID: 17051334
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis.
Zhang XD; Gillespie SK; Borrow JM; Hersey P
Biochem Pharmacol; 2003 Oct; 66(8):1537-45. PubMed ID: 14555232
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
